GW Pharmaceuticals PLC- (NASDAQ:GWPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Monday.

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

A number of other analysts have also commented on GWPH. Bank of America decreased their price target on shares of GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating for the company in a research note on Tuesday, November 14th. Cantor Fitzgerald restated a “buy” rating and set a $208.00 price target on shares of GW Pharmaceuticals PLC- in a research note on Monday, November 20th. Goldman Sachs Group upgraded shares of GW Pharmaceuticals PLC- from a “neutral” rating to a “buy” rating and set a $174.00 target price for the company in a research note on Thursday, December 14th. BidaskClub upgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. Finally, Leerink Swann reiterated a “buy” rating and issued a $153.00 target price on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, January 23rd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $146.38.

Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) traded up $1.28 during mid-day trading on Monday, reaching $127.34. 268,704 shares of the company’s stock were exchanged, compared to its average volume of 426,503. The company has a market cap of $3,230.00, a price-to-earnings ratio of -14.40 and a beta of 2.50. The company has a quick ratio of 11.34, a current ratio of 11.44 and a debt-to-equity ratio of 0.01. GW Pharmaceuticals PLC- has a fifty-two week low of $92.65 and a fifty-two week high of $143.37.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.03) by ($0.40). The business had revenue of $7.73 million for the quarter, compared to the consensus estimate of $2.18 million. GW Pharmaceuticals PLC- had a negative net margin of 1,357.98% and a negative return on equity of 46.94%. research analysts anticipate that GW Pharmaceuticals PLC- will post -9.18 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of GWPH. Wells Fargo & Company MN grew its position in GW Pharmaceuticals PLC- by 21.8% during the second quarter. Wells Fargo & Company MN now owns 13,962 shares of the biopharmaceutical company’s stock valued at $1,399,000 after buying an additional 2,500 shares during the period. Ameriprise Financial Inc. grew its position in GW Pharmaceuticals PLC- by 8.5% during the second quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 162 shares during the period. Advisor Group Inc. grew its position in GW Pharmaceuticals PLC- by 10.7% during the second quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 145 shares during the period. Stifel Financial Corp grew its position in GW Pharmaceuticals PLC- by 24.4% during the second quarter. Stifel Financial Corp now owns 18,716 shares of the biopharmaceutical company’s stock valued at $1,885,000 after buying an additional 3,676 shares during the period. Finally, HighTower Advisors LLC grew its position in GW Pharmaceuticals PLC- by 40.2% during the second quarter. HighTower Advisors LLC now owns 2,865 shares of the biopharmaceutical company’s stock valued at $290,000 after buying an additional 821 shares during the period. Institutional investors own 74.75% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “GW Pharmaceuticals PLC- (GWPH) Lowered to “Sell” at Zacks Investment Research” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://theolympiareport.com/2018/02/13/gw-pharmaceuticals-plc-gwph-lowered-to-sell-at-zacks-investment-research.html.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.